<code id='420EC0DD48'></code><style id='420EC0DD48'></style>
      • <acronym id='420EC0DD48'></acronym>
      <center id='420EC0DD48'><center id='420EC0DD48'><tfoot id='420EC0DD48'></tfoot></center><abbr id='420EC0DD48'><dir id='420EC0DD48'><tfoot id='420EC0DD48'></tfoot><noframes id='420EC0DD48'>
      • <optgroup id='420EC0DD48'><strike id='420EC0DD48'><sup id='420EC0DD48'></sup></strike><code id='420EC0DD48'></code></optgroup>
        5. <b id='420EC0DD48'><label id='420EC0DD48'><select id='420EC0DD48'><dt id='420EC0DD48'><span id='420EC0DD48'></span></dt></select></label></b><u id='420EC0DD48'></u>
          <i id='420EC0DD48'><strike id='420EC0DD48'><tt id='420EC0DD48'><pre id='420EC0DD48'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-28 23:36:52 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：2493
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          STAT Summit: The economic case for universal basic health care
                                
                            
          Next article：  
                                      
                                          Drug repurposing or repositioning? The language matters
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles